A Southern District of New York jury delivered the first plaintiff’s verdict recorded in the multidistrict litigation over the anti-bone loss drug Fosamax. A jury in Judge John Keenan’s courtroom took about four hours to decide that Merck & Co. should pay $8 million for present and future pain and suffering to Shirley Boles of Fort Walton, Fla., said Gary Douglas of Douglas & London, who represented Boles along with Timothy M. O’Brien of Levin Papantonio of Pensacola, Fla.
Boles is one of some 900 plaintiffs who filed suit in federal and state courts alleging that instead of offsetting the bone loss associated with menopause, Fosamax caused deterioration of the jawbone. Paul F. Strain of Venable represented Merck. The trial, which began on June 7, was the second for Boles. The first one ended in a mistrial in September after jurors, who could be heard by lawyers arguing vehemently in the jury room, deadlocked 7-1 in favor of the pharmaceutical company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
